William Blair Brokers Boost Earnings Estimates for DNLI

Key Points

• William Blair increased their Q3 2025 EPS estimate for Denali Therapeutics from ($0.84) to ($0.77) per share, maintaining a "Strong-Buy" rating on the stock.
• Denali Therapeutics reported Q2 earnings of (0.72) EPS, surpassing the consensus estimates of (0.74) EPS.
• Analyst ratings show strong support for Denali, with thirteen buy ratings and an average price target of $33.85.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at William Blair lifted their Q3 2025 EPS estimates for Denali Therapeutics in a research report issued on Tuesday, August 12th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.77) per share for the quarter, up from their prior estimate of ($0.84). William Blair has a "Strong-Buy" rating on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. William Blair also issued estimates for Denali Therapeutics' Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.49) EPS, FY2027 earnings at ($2.78) EPS and FY2028 earnings at ($0.41) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the prior year, the business posted ($0.59) earnings per share.

A number of other analysts have also commented on the stock. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Bank of America lowered their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Robert W. Baird lowered their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. HC Wainwright lowered their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Wedbush decreased their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of "Buy" and an average price target of $33.85.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $14.81 on Thursday. The company's fifty day simple moving average is $14.29 and its 200-day simple moving average is $15.48. The company has a quick ratio of 9.56, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.17 billion, a PE ratio of -5.29 and a beta of 1.36. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33.

Insiders Place Their Bets

In related news, CEO Ryan J. Watts sold 495,282 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the completion of the sale, the chief executive officer owned 253,071 shares of the company's stock, valued at $3,796,065. This represents a 66.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 12.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DNLI. Sterling Capital Management LLC lifted its holdings in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after acquiring an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Denali Therapeutics in the first quarter worth about $41,000. GF Fund Management CO. LTD. bought a new position in shares of Denali Therapeutics in the fourth quarter worth about $62,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of Denali Therapeutics in the fourth quarter worth about $65,000. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.